Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection
Authors
Keywords
-
Journal
INFLAMMOPHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-20
DOI
10.1007/s10787-021-00903-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Compassionate use of Ruxolitinib in patients with SarsCov‐2 infection not on mechanical ventilation. Short‐term effects on inflammation and ventilation
- (2021) Andrea Mortara et al. CTS-Clinical and Translational Science
- Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study
- (2021) Ismael Francisco Aomar-Millán et al. Internal and Emergency Medicine
- Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial
- (2021) Serge Bureau et al. Lancet Respiratory Medicine
- Effectiveness of anakinra for tocilizumab-refractory severe COVID-19. A single centre retrospective comparative study
- (2021) Cristina de la Calle et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia
- (2021) Emanuele Pontali et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study
- (2021) Marco Franzetti et al. JOURNAL OF IMMUNOLOGY
- Baricitinib Therapy in Covid-19 Pneumonia — An Unmet Need Fulfilled
- (2021) Delia Goletti et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
- (2021) NEW ENGLAND JOURNAL OF MEDICINE
- Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study
- (2021) Christopher T Rentsch et al. BMJ-British Medical Journal
- An open label trial of anakinra to prevent respiratory failure in COVID-19
- (2021) Evdoxia Kyriazopoulou et al. eLife
- Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2021) François-Xavier Lescure et al. Lancet Respiratory Medicine
- Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh
- (2021) Md. Jahidul Hasan et al. BMC INFECTIOUS DISEASES
- SARS-CoV-2 incidence and vaccine escape
- (2021) Robin N Thompson et al. LANCET INFECTIOUS DISEASES
- Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation
- (2021) Emanuel Della-Torre et al. Frontiers in Immunology
- The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19
- (2021) Heloísa Antoniella Braz-de-Melo et al. Frontiers in Medicine
- A cohort autopsy study defines COVID-19 systemic pathogenesis
- (2021) Xiao-Hong Yao et al. CELL RESEARCH
- Combating the progression of novel coronavirus SARS-CoV-2 infectious Disease: Current state and future prospects in molecular diagnostic and drug discovery
- (2021) Arbind Kumar et al. CURRENT MOLECULAR MEDICINE
- Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study
- (2021) Yutaka Umemura et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Surviving Covid-19 with Heparin?
- (2021) Hugo ten Cate NEW ENGLAND JOURNAL OF MEDICINE
- Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID-19—Mechanisms and Therapeutic Targets
- (2021) Adriana Fodor et al. Oxidative Medicine and Cellular Longevity
- Management of COVID-19-induced cytokine storm by Keap1-Nrf2 system: a review
- (2021) Ekta Singh et al. INFLAMMOPHARMACOLOGY
- JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy
- (2021) Alessandro Maria Vannucchi et al. Journal of Clinical Medicine
- Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial
- (2021) Paul C Cremer et al. Lancet Rheumatology
- Efficacy and Safety of Sarilumab in patients with COVID19 Pneumonia: A Randomized, Phase III Clinical Trial (SARTRE Study)
- (2021) Aránzazu Sancho-López et al. Infectious Diseases and Therapy
- Different signaling pathways involved in the anti-inflammatory effects of unfractionated heparin on lipopolysaccharide-stimulated human endothelial cells
- (2020) Xu Li et al. Journal of Inflammation-London
- A novel coronavirus outbreak of global health concern
- (2020) Chen Wang et al. LANCET
- Pathological findings of COVID-19 associated with acute respiratory distress syndrome
- (2020) Zhe Xu et al. Lancet Respiratory Medicine
- Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
- (2020) Jean-Jacques Kiladjian et al. Lancet Haematology
- Initial ELSO Guidance Document
- (2020) Robert H. Bartlett et al. ASAIO JOURNAL
- Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
- (2020) Paola Toniati et al. AUTOIMMUNITY REVIEWS
- Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes
- (2020) James T. England et al. BLOOD REVIEWS
- Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
- (2020) Daniel Blanco-Melo et al. CELL
- Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
- (2020) Evangelos J. Giamarellos-Bourboulis et al. Cell Host & Microbe
- Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
- (2020) Justin Stebbing et al. EMBO Molecular Medicine
- Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
- (2020) Ruggero Capra et al. European Journal of Internal Medicine
- Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation
- (2020) Daniel E. Leisman et al. INTENSIVE CARE MEDICINE
- Use of anakinra in severe COVID-19: a case report
- (2020) Giovanni Filocamo et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
- (2020) Yang Cao et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
- (2020) Tobias Herold et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Clinical and immunological features of severe and moderate coronavirus disease 2019
- (2020) Guang Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
- (2020) Fabrizio Cantini et al. JOURNAL OF INFECTION
- Tocilizumab treatment in COVID-19: A single center experience
- (2020) Pan Luo et al. JOURNAL OF MEDICAL VIROLOGY
- Tocilizumab for the treatment of severe coronavirus disease 2019
- (2020) Rand Alattar et al. JOURNAL OF MEDICAL VIROLOGY
- COVID‐19 pneumonia treated with Sarilumab: a clinical series of eight patients
- (2020) Maurizio Benucci et al. JOURNAL OF MEDICAL VIROLOGY
- Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19
- (2020) Ishan Paranjpe et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy
- (2020) Ning Tang et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- The association between treatment with heparin and survival in patients with Covid-19
- (2020) Luis Ayerbe et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- COVID-19: consider cytokine storm syndromes and immunosuppression
- (2020) Puja Mehta et al. LANCET
- Covid-19 in Critically Ill Patients in the Seattle Region — Case Series
- (2020) Pavan K. Bhatraju et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effective treatment of severe COVID-19 patients with tocilizumab
- (2020) Xiaoling Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Heparin as a therapy for COVID-19: current evidence and future possibilities
- (2020) Joseph A. Hippensteel et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
- (2020) Emanuel Della-Torre et al. ANNALS OF THE RHEUMATIC DISEASES
- Amelioration of COVID‐19‐related cytokine storm syndrome: parallels to chimeric antigen receptor‐T cell cytokine release syndrome
- (2020) Ryan L. Hoiland et al. BRITISH JOURNAL OF HAEMATOLOGY
- Use of Baricitinib in Patients with Moderate and Severe COVID-19
- (2020) Boghuma K Titanji et al. CLINICAL INFECTIOUS DISEASES
- SARS-CoV-2 infection: The role of cytokines in COVID-19 disease
- (2020) Víctor J. Costela-Ruiz et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19
- (2020) Suman Rohilla DRUG DEVELOPMENT RESEARCH
- Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab
- (2020) A. Cingolani et al. INFECTION
- Early administration of Interleukin-6 inhibitors for patients with severe Covid-19 disease is associated with decreased intubation, reduced mortality, and increased discharge
- (2020) Pranay Sinha et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Early Identification of COVID-19 Cytokine Storm and Treatment with Anakinra or Tocilizumab
- (2020) Annette Langer-Gould et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- IL-6–based mortality risk model for hospitalized patients with COVID-19
- (2020) Rocio Laguna-Goya et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent
- (2020) Alessio Mazzoni et al. JOURNAL OF CLINICAL INVESTIGATION
- The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
- (2020) Qing Ye et al. JOURNAL OF INFECTION
- The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
- (2020) F. La Rosée et al. LEUKEMIA
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID‐19
- (2020) Sarah C.J. Jorgensen et al. PHARMACOTHERAPY
- Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19
- (2020) Raphaël Cauchois et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Is a “Cytokine Storm” Relevant to COVID-19?
- (2020) Pratik Sinha et al. JAMA Internal Medicine
- Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID‐19: A Case Series
- (2020) Iris Navarro‐Millán et al. Arthritis & Rheumatology
- Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities
- (2020) Puja Mehta et al. Lancet Respiratory Medicine
- Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies
- (2020) Aldo Bonaventura et al. Frontiers in Immunology
- Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper
- (2020) Sonu Bhaskar et al. Frontiers in Immunology
- The COVID-19 Cytokine Storm; What We Know So Far
- (2020) Dina Ragab et al. Frontiers in Immunology
- Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
- (2020) Vincenzo Montesarchio et al. Journal for ImmunoTherapy of Cancer
- Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol
- (2020) Enrico Capochiani et al. Frontiers in Medicine
- Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action
- (2020) Hassan Yousefi et al. BIOCHEMICAL PHARMACOLOGY
- A whole blood test to measure SARS-CoV-2 specific response in COVID-19 patients
- (2020) Linda Petrone et al. CLINICAL MICROBIOLOGY AND INFECTION
- Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
- (2020) Alessandro M. Vannucchi et al. LEUKEMIA
- GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Control Study
- (2020) Zelalem Temesgen et al. MAYO CLINIC PROCEEDINGS
- A dynamic COVID-19 immune signature includes associations with poor prognosis
- (2020) Adam G. Laing et al. NATURE MEDICINE
- Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
- (2020) John H. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin‐6 in Covid‐19: A systematic review and meta‐analysis
- (2020) Eric A. Coomes et al. REVIEWS IN MEDICAL VIROLOGY
- Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents
- (2020) Sumanth Khadke et al. Virology Journal
- Preemptive interleukin-6 blockade in patients with COVID-19
- (2020) Lucía Guillén et al. Scientific Reports
- Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines
- (2020) Antonella Fara et al. Open Biology
- Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
- (2020) Shruti Gupta et al. JAMA Internal Medicine
- Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
- (2020) Olivier Hermine et al. JAMA Internal Medicine
- Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia
- (2020) Carlo Salvarani et al. JAMA Internal Medicine
- A comprehensive review on sarilumab in COVID-19
- (2020) Sajad Khiali et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- (2020) Andre C. Kalil et al. NEW ENGLAND JOURNAL OF MEDICINE
- C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19
- (2020) Milad Sharifpour et al. PLoS One
- Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany
- (2020) Hendrik Streeck et al. Nature Communications
- Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study
- (2020) A. Balkhair et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study
- (2020) Giorgio Bozzi et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome
- (2019) Chelsea Kotch et al. Expert Review of Clinical Immunology
- Management of cytokine release syndrome related to CAR-T cell therapy
- (2019) Hongli Chen et al. Frontiers of Medicine
- Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial
- (2019) Asra Ahmed et al. Lancet Haematology
- GM-CSF in inflammation
- (2019) John A. Hamilton JOURNAL OF EXPERIMENTAL MEDICINE
- C-reactive protein as a biomarker of severe H1N1 influenza
- (2018) Denitsa Vasileva et al. INFLAMMATION RESEARCH
- Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis
- (2017) T. Iba et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritis
- (2017) S.-C. Bae et al. ZEITSCHRIFT FUR RHEUMATOLOGIE
- Chemokines and Chemokine Receptors in Lymphoid Tissue Dynamics
- (2016) Olga Schulz et al. Annual Review of Immunology
- IL-6 pathway in the liver: From physiopathology to therapy
- (2016) Dirk Schmidt-Arras et al. JOURNAL OF HEPATOLOGY
- Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients
- (2016) Jae-Hoon Ko et al. JOURNAL OF INFECTION
- SARS and MERS: recent insights into emerging coronaviruses
- (2016) Emmie de Wit et al. NATURE REVIEWS MICROBIOLOGY
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
- (2014) Frits van Rhee et al. LANCET ONCOLOGY
- GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia
- (2013) E. Padron et al. BLOOD
- Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate Proteoglycans
- (2011) Jianshe Lang et al. PLoS One
- The anti-inflammatory effects of heparin and related compounds
- (2007) Edward Young THROMBOSIS RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now